Related Experiment Video
Updated: Apr 30, 2026
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Current and investigational drug strategies for glioblastoma
M Ajaz1, S Jefferies2, L Brazil3
1Surrey Cancer Research Institute, University of Surrey, Guildford, UK.
Abstract:
Medical treatments for glioblastoma face several challenges. Lipophilic alkylators remain the mainstay of treatment, emphasising the primacy of good blood-brain barrier penetration. Temozolomide has emerged as a major contributor to improved patient survival. The roles of procarbazine and vincristine in the procarbazine, lomustine and vincristine (PCV) schedule have attracted scrutiny and several lines of evidence now support the use of lomustine as effective single-agent therapy. Bevacizumab has had a convoluted development history, but clearly now has no major role in first-line treatment, and may even be detrimental to quality of life in this setting. In later disease, clinically meaningful benefits are achievable in some patients, but more impressively the combination of bevacizumab and lomustine shows early promise. Over the last decade, investigational strategies in glioblastoma have largely subscribed to the targeted kinase inhibitor paradigm and have mostly failed. Low prevalence dominant driver lesions such as the FGFR-TACC fusion may represent a niche role for this agent class. Immunological, metabolic and radiosensitising approaches are being pursued and offer more generalised efficacy. Finally, trial design is a crucial consideration. Progress in clinical glioblastoma research would be greatly facilitated by improved methodologies incorporating: (i) routine pharmacokinetic and pharmacodynamic assessments by preoperative dosing; and (ii) multi-stage, multi-arm protocols incorporating new therapy approaches and high-resolution biology in order to guide necessary improvements in science.
Insights
Current glioblastoma treatments like temozolomide are effective, but challenges remain. New research explores lomustine, bevacizumab combinations, and novel strategies like immunotherapy for improved patient survival and quality of life.
Area of Science:
- Neuro-oncology
- Clinical trial design
- Pharmacology
Background:
- Glioblastoma treatment faces challenges, with lipophilic alkylators like temozolomide being standard care.
- The efficacy of combination therapies and newer agents requires further investigation.
- Optimizing clinical trial methodologies is crucial for advancing glioblastoma research.
Purpose of the Study:
- To review current glioblastoma treatment strategies and their limitations.
- To evaluate the efficacy of established and emerging therapies, including lomustine and bevacizumab.
- To highlight the importance of improved clinical trial design for future research.
Main Methods:
- Review of existing literature on glioblastoma treatment.
- Analysis of the roles of temozolomide, lomustine, procarbazine, vincristine, and bevacizumab.
- Discussion of investigational approaches including targeted inhibitors, immunotherapy, and metabolic strategies.
Main Results:
- Temozolomide remains a key agent, while lomustine shows promise as monotherapy.
- Bevacizumab has limited first-line utility but may benefit later-stage disease, especially in combination with lomustine.
- Targeted kinase inhibitors have largely failed, except for specific genetic alterations.
- Immunological, metabolic, and radiosensitizing approaches show potential for broader efficacy.
Conclusions:
- Glioblastoma treatment requires a multi-faceted approach, moving beyond traditional alkylators.
- Future research must incorporate advanced trial designs, including pharmacokinetic/pharmacodynamic assessments and high-resolution biology.
- Novel therapeutic strategies offer hope for improved outcomes in glioblastoma patients.
More Related Videos
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014